Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea

• Published in: Cancer research and treatment Vol. 48; no. 1; pp. 393 - 397
• Main Authors: Jo, Jaemin, Kim, Jung Ho, Kim, Ji Young, Hyun, Changlim, Rhee, Jiyoung, Kwon, Jungmi, Han, Sanghoon, Kim, Wookun
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Cancer Association 01.01.2016; 대한암학회
• Subjects: Aged; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - secondary; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Case Report; Disease-Free Survival; Humans; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Male; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Republic of Korea; Sulfonamides - pharmacology; Sulfonamides - therapeutic use; Treatment Outcome; 의약학; Drug therapy; Tyrosine kinase inhibitor; Pazopanib; Lung neoplasms
• ISSN: 1598-2998; 2005-9256
• DOI: 10.4143/crt.2014.209

Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors' knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.